Austin Clinical Site
Austin, Texas, 78744, United States
NCT Number: NCT01106664
The primary objective of this study is to evaluate the safety and tolerability of NON-7746 in healthy adult subjects. The secondary objectives are to characterize the pharmacokinetic and pharmacodynamic profiles of ONO-7746 and to evaluate the food effect on the PK profile of ONO-7746 when administered with or without a meal.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Austin, Texas, 78744, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
1mg, 2mg, 4mg, 8mg, 16mg, once daily for multiple-dose study; 4mg at a single dose for food effect study.
Time frame: up to 42 days
(evaluations of physical examinations, vital signs, 12-lead ECG, slit lamp examinations, safety laboratory tests, and surveillance for adverse events)
Time frame: up to 42 days
Time frame: up to 42 days
Ono Pharmaceutical Co., Ltd.
Industry
A Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study and Food Effect Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-7746 in Healthy Adult Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04481750
Healthy Adult Subjects
Osaka, Japan
View Trial DetailsNCT04493281
Healthy Adult Subjects
Tokyo, Japan
View Trial DetailsNCT04776135
Healthy Adult Subjects
Tokyo, Toshima-ku, Japan
View Trial DetailsNCT04029090
Healthy Adult Subjects
Tokyo, Japan
View Trial Details